Bayer and Rentschler join forces to produce CureVac’s vaccine
German biotech company CureVac aims to produce up to 300-million doses in 2021 and between 600-million and 1-billion doses in 2022
01 February 2021 - 16:57
Berlin/Frankfurt — CureVac has signed up pharmaceuticals giant Bayer and contract drugmaker Rentschler to help to produce its experimental Covid-19 vaccine, joining the global push to boost vaccine supplies.
German biotech company CureVac, which began late-stage testing of the vaccine in December and expects to announce interim results this quarter, said it aims to produce up to 300-million doses in 2021 and between 600-million and 1-billion doses in 2022...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.